Zentek Ltd. announced on November 25 that Mohammed (Moe) Jiwan will take the helm as chief executive officer, effective December 1, 2025, after the resignation of former CEO Greg Fenton on September 3. Fenton’s departure followed a letter of intent with Altek Advanced Materials, in which he will serve as full‑time CEO and join Zentek’s advisory board.
Jiwan brings a decade of experience in scaling high‑growth technology companies, having led several startups from seed to exit. His track record includes securing capital, structuring public‑company transactions, and driving commercialization in the healthcare and life‑sciences sectors. Management believes his expertise will accelerate the commercialization of Zentek’s graphene‑based products, particularly the ZenGUARD antimicrobial coating and Albany Graphite for nuclear applications.
Zentek’s financial profile underscores the urgency of the leadership change. The company’s stock has fallen more than 50 % in the past six months, and analysts cite negative profit margins and cash‑flow challenges. In a recent briefing, Chair John Snisarenko said the appointment “marks the beginning of a disciplined transformation of our Company” and that Jiwan’s experience in capital markets will help secure the funding needed to move products from R&D to market.
Jiwan echoed this sentiment, stating, “We are at a meaningful inflection point. Our mandate is to unlock the full value of our technologies, secure the capital required to grow, and deliver on the commercial progress our shareholders deserve.” The new CEO’s focus on commercialization aligns with Zentek’s strategic pivot from research to market‑ready solutions, a shift that management believes will stabilize cash flow and improve profitability.
While the appointment signals a new strategic direction, investors should note that Zentek remains in a precarious financial position. The company’s recent private placement raised $2.47 million, and its latest quarterly results showed continued negative margins. Jiwan’s leadership will be tested by the need to balance aggressive commercialization with disciplined cost management to restore financial health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.